Jessie K Edwards1, Peter Arimi2, Freddie Ssengooba3, Michael E Herce4,5, Grace Mulholland1, Milissa Markiewicz6, Susan Babirye3, Steven Ssendagire3, Sharon S Weir1,6. 1. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2. U.S. Agency for International Development, Kenya/East Africa Regional Mission, Nairobi, Kenya. 3. Makerere University School of Public Health, Kampala, Uganda. 4. Institute for Global Health & Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 5. Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia. 6. Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract
OBJECTIVE: The aim of this study was to evaluate HIV testing yield under several candidate strategies for outreach testing at venues (i.e. places where people socialize and meet new sex partners) in East Africa cross-border areas. DESIGN: Population-based cross-sectional biobehavioural survey of people who had not been previously diagnosed with HIV found in venues. METHODS: We identified participants who would have been tested for HIV under each of 10 hypothetical outreach testing strategies and calculated the proportion who would have newly tested positive for HIV under each strategy. On the basis of this proportion, we calculated the 'number needed to test' (NNT) to identify one new case of HIV under each strategy. All estimates were obtained by applying survey sampling weights to account for the complex sampling design. RESULTS: If testing was performed at a random sample of venues, 35 people would need to be tested to identify one new case of HIV, but higher yield could be found by limiting testing to venues with specific characteristics. Strategies focusing on women had higher testing yield. Testing women employed by venues would result in highest yield of all strategies examined (NNT = 15), while testing men under age 24 would result in the lowest yield (NNT = 99). CONCLUSION: Quantitatively evaluating HIV testing strategies prior to implementation using survey data presents a new opportunity to refine and prioritize outreach testing strategies for the people and places most likely to result in high HIV testing yield.
OBJECTIVE: The aim of this study was to evaluate HIV testing yield under several candidate strategies for outreach testing at venues (i.e. places where people socialize and meet new sex partners) in East Africa cross-border areas. DESIGN: Population-based cross-sectional biobehavioural survey of people who had not been previously diagnosed with HIV found in venues. METHODS: We identified participants who would have been tested for HIV under each of 10 hypothetical outreach testing strategies and calculated the proportion who would have newly tested positive for HIV under each strategy. On the basis of this proportion, we calculated the 'number needed to test' (NNT) to identify one new case of HIV under each strategy. All estimates were obtained by applying survey sampling weights to account for the complex sampling design. RESULTS: If testing was performed at a random sample of venues, 35 people would need to be tested to identify one new case of HIV, but higher yield could be found by limiting testing to venues with specific characteristics. Strategies focusing on women had higher testing yield. Testing women employed by venues would result in highest yield of all strategies examined (NNT = 15), while testing men under age 24 would result in the lowest yield (NNT = 99). CONCLUSION: Quantitatively evaluating HIV testing strategies prior to implementation using survey data presents a new opportunity to refine and prioritize outreach testing strategies for the people and places most likely to result in high HIV testing yield.
Authors: Esther Kissling; Edward H Allison; Janet A Seeley; Steven Russell; Max Bachmann; Stanley D Musgrave; Simon Heck Journal: AIDS Date: 2005-11-18 Impact factor: 4.177
Authors: Kathleen J Sikkema; Melissa H Watt; Christina S Meade; Krista W Ranby; Seth C Kalichman; Donald Skinner; Desiree Pieterse Journal: J Acquir Immune Defic Syndr Date: 2011-07-01 Impact factor: 3.731
Authors: Niklaus D Labhardt; Isaac Ringera; Thabo I Lejone; Thomas Klimkait; Josephine Muhairwe; Alain Amstutz; Tracy R Glass Journal: JAMA Date: 2018-03-20 Impact factor: 56.272
Authors: Lori A J Scott-Sheldon; Paige Walstrom; Kate B Carey; Blair T Johnson; Michael P Carey Journal: Curr HIV/AIDS Rep Date: 2013-12 Impact factor: 5.071
Authors: Kristina E Bowles; Hollie A Clark; Eric Tai; Patrick S Sullivan; Binwei Song; Jenny Tsang; Craig A Dietz; Julita Mir; Azul Mares-DelGrasso; Cindy Calhoun; Daisy Aguirre; Cicily Emerson; James D Heffelfinger Journal: Public Health Rep Date: 2008 Nov-Dec Impact factor: 2.792
Authors: Marguerita A Lightfoot; Chadwick K Campbell; Nicholas Moss; Sarah Treves-Kagan; Emily Agnew; Mi-Suk Kang Dufour; Hyman Scott; Aria M Saʼid; Sheri A Lippman Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Maya Petersen; Laura Balzer; Dalsone Kwarsiima; Norton Sang; Gabriel Chamie; James Ayieko; Jane Kabami; Asiphas Owaraganise; Teri Liegler; Florence Mwangwa; Kevin Kadede; Vivek Jain; Albert Plenty; Lillian Brown; Geoff Lavoy; Joshua Schwab; Douglas Black; Mark van der Laan; Elizabeth A Bukusi; Craig R Cohen; Tamara D Clark; Edwin Charlebois; Moses Kamya; Diane Havlir Journal: JAMA Date: 2017-06-06 Impact factor: 56.272
Authors: Sharon S Weir; M Giovanna Merli; Jing Li; Anisha D Gandhi; William W Neely; Jessie K Edwards; Chirayath M Suchindran; Gail E Henderson; Xiang-Sheng Chen Journal: Sex Transm Infect Date: 2012-12 Impact factor: 3.519
Authors: Linah K Mwango; Kristen A Stafford; Natalia C Blanco; Marie-Claude Lavoie; Morley Mujansi; Nasho Nyirongo; Kalima Tembo; Henry Sakala; Julian Chipukuma; Beauty Phiri; Carol Nzangwa; Susan Mwandila; Kennedy C Nkwemu; Ahmed Saadani; Annie Mwila; Michael E Herce; Cassidy W Claassen Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: Christine A West; Gregory C Chang; Dustin W Currie; Rachel Bray; Steve Kinchen; Stephanie Behel; Rachel McCullough-Sanden; Andrea Low; Anne Bissek; Judith D Shang; Clement B Ndongmo; Emily K Dokubo; Shirish Balachandra; Legre R Lobognon; Lenhle Dube; Harriet Nuwagaba-Biribonwoha; Michelle Li; Munyaradzi Pasipamire; Yimam Getaneh; Sileshi Lulseged; Frehywot Eshetu; Leonard Kingwara; Emily Zielinski-Gutierrez; Mphotleng Tlhomola; Puleng Ramphalla; Thokozani Kalua; Andrew F Auld; Daniel B Williams; Eric Remera; Gallican N Rwibasira; Veronicah Mugisha; Samuel S Malamba; Jeremiah Mushi; Mohamed F Jalloh; George S Mgomella; Wilford L Kirungi; Sam Biraro; Anna C Awor; Danielle T Barradas; Owen Mugurungi; John H Rogers; Megan Bronson; Stephane M Bodika; Aderonke Ajiboye; Nicholas Gaffga; Carole Moore; Hetal K Patel; Andrew C Voetsch Journal: J Acquir Immune Defic Syndr Date: 2021-08-01 Impact factor: 3.771